Press Release: aap: Successful start in 2015 with 45% LOQTEQ(R) sales increase and 23% growth in biomaterials business

aap Implantate AG / aap: Successful start in 2015 with 45% LOQTEQ(R) sales increase and 23% growth in biomaterials business . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

aap Implantate AG (XETRA: AAQ.DE) made a successful start to financial year 2015 with significant sales growth. According to preliminary figures, sales increased in the first three months of this year compared to the corresponding period in the last year by 16% to EUR 7.1 million (Q1/2014: EUR 6.1 million). Thereby the company exceeded its guidance provided in February of EUR 6.5 million to EUR 7.0 million.

Sales in EUR million Q1/2015 Q1/2014 Change on year Trauma 2.5 2.2 15% thereof LOQTEQ(R) 1.7 1.1 45% Biomaterials 4.4 3.6 23% Projects 0.1 0.1 109% Other 0.1 0.2 -81% Total sales 7.1 6.1 16%

The growth drivers of this positive sales performance in the first three months of the current financial year were the LOQTEQ(R) product family and the biomaterials business. aap Implantate AG significantly increased sales with the LOQTEQ(R) portfolio in the first quarter of 2015 year-on-year by 45% to EUR 1.7 million (Q1/2014: EUR 1.1 million). Performance in the reporting period testifies to the anatomic plate system continuing to establish itself in the market.

Sustained by the significant growth in LOQTEQ(R) product sales, aap Implantate AG's overall sales in the trauma business rose year-on-year by 15% to EUR 2.5 million (Q1/2014: EUR 2.2 million). On a full year basis the company's target is to achieve sales growth of more than 20% in the trauma business. In order to achieve this target, aap Implantate AG intends to expand the LOQTEQ(R) product family further in the current financial year and thereby achieving an indication coverage of more than 90%. Furthermore the company plans to push the internationalisation with a focus on the US American market.

In the biomaterials business the company also achieved a significant sales increase in the first quarter of 2015. Sales grew in the reporting period compared to the first three months of financial year 2014 by 23% to EUR 4.4 million (Q1/2014: EUR 3.6 million). The growth driver in the first quarter of the current year was in particular the bone cement business with global leading companies.

Overall, it can be furthermore stated that aap Implantate AG generates dynamic sales growth and pushes geographic expansion with its innovative and IP protected LOQTEQ(R) products, while the biomaterials business is characterized by continuous and profitable growth with strong cash flows.

The preliminary results contained in this press release are based on management's initial analysis of operations for the period ended on 31 March 2015, and are therefore subject to change. aap Implantate AG plans to announce its final results for the first quarter of 2015 on 15 May 2015.

About aap Implantate AG

aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: aap Implantate AG via Globenewswire

HUG#1910895

--- End of Message ---

aap Implantate AG

Lorenzweg 5 Berlin Germany

WKN: 506660;ISIN: DE0005066609;

Listed: Freiverkehr in Börse Stuttgart,

Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,

Freiverkehr in Börse Berlin,

Freiverkehr in Börse Düsseldorf,

Freiverkehr in Bayerische Börse München,

Freiverkehr in Niedersächsische Börse zu Hannover,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse;

http://www.aap.de (END) Dow Jones Newswires

   April 14, 2015 04:08 ET (08:08 GMT)- - 04 08 AM EDT 04-14-15